Keywords
Last Name
Institution

James McGettigan

TitleAsst Professor
InstitutionThomas Jefferson University
DepartmentMicrobiology
Address1020 Locust St.
Philadelphia PA 19107
Phone215-503-4629
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R21AI070252     (MCGETTIGAN, JAMES P)Jul 15, 2006 - Jun 30, 2009
    NIH/NIAID
    Second Generation Rabies Vaccines
    Role: Principal Investigator

    R42AI081334     (MCGETTIGAN, JAMES P)Dec 1, 2008 - Jul 31, 2014
    NIH/NIAID
    Human Rabies Virus Vaccine Development
    Role: Principal Investigator

    R41AI081334     (MCGETTIGAN, JAMES P)Apr 1, 2009 - Sep 30, 2010
    NIH/NIAID
    Human Rabies Virus Vaccine Development
    Role: Principal Investigator

    R01AI079211     (MCGETTIGAN, JAMES P)Jul 15, 2009 - Jun 30, 2014
    NIH/NIAID
    Replication-deficient rabies vectors against rabies infection
    Role: Principal Investigator

    R21AI096907     (MCGETTIGAN, JAMES P)Jul 1, 2012 - Jun 30, 2014
    NIH/NIAID
    Antibody Responses to a Novel HIV-1 Vaccine Vector
    Role: Principal Investigator

    R21AI109135     (MCGETTIGAN, JAMES P)May 15, 2014 - Apr 30, 2016
    NIH/NIAID
    Novel rabies virus vaccines that exploit innate immune signals
    Role: Principal Investigator

    R56AI123272     (MCGETTIGAN, JAMES P)May 9, 2016 - Apr 30, 2017
    NIH/NIAID
    Development of a single-dose rabies vaccine
    Role: Principal Investigator

    R01AI123272     (MCGETTIGAN, JAMES P)Nov 22, 2016 - Oct 31, 2021
    NIH/NIAID
    Development of a single-dose rabies virus vaccine
    Role: Principal Investigator

    R21AI135361     (MCGETTIGAN, JAMES P)May 16, 2018 - Apr 30, 2020
    NIH/NIAID
    Development of Rabies-based Virus-like Particles
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Haley SL, Tzvetkov EP, Lytle AG, Alugupalli KR, Plummer JR, McGettigan JP. APRIL:TACI axis is dispensable for the immune response to rabies vaccination. Antiviral Res. 2017 Jun 12; 144:130-137. PMID: 28619678.
      View in: PubMed
    2. Haley SL, Tzvetkov EP, Meuwissen S, Plummer JR, McGettigan JP. Targeting Vaccine-Induced Extrafollicular Pathway of B Cell Differentiation Improves Rabies Postexposure Prophylaxis. J Virol. 2017 Apr 15; 91(8). PMID: 28148792.
      View in: PubMed
    3. Dunkel A, Shen S, LaBranche CC, Montefiori D, McGettigan JP. A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses. AIDS Res Hum Retroviruses. 2015 Nov; 31(11):1126-38. PMID: 25848984.
      View in: PubMed
    4. Lytle AG, Shen S, McGettigan JP. Lymph node but not intradermal injection site macrophages are critical for germinal center formation and antibody responses to rabies vaccination. J Virol. 2015 Mar 1; 89(5):2842-8. PMID: 25540370.
      View in: PubMed
    5. McGettigan JP, David F, Figueiredo MD, Minke J, Mebatsion T, Schnell MJ. Safety and serological response to a matrix gene-deleted rabies virus-based vaccine vector in dogs. Vaccine. 2014 Mar 26; 32(15):1716-9. PMID: 24508037.
      View in: PubMed
    6. Norton JE, Lytle AG, Shen S, Tzvetkov EP, Dorfmeier CL, McGettigan JP. ICAM-1-Based Rabies Virus Vaccine Shows Increased Infection and Activation of Primary Murine B Cells In Vitro and Enhanced Antibody Titers In-Vivo. PLoS One. 2014; 9(1):e87098. PMID: 24489846.
      View in: PubMed
    7. Lawrence TM, Wanjalla CN, Gomme EA, Wirblich C, Gatt A, Carnero E, GarcĂ­a-Sastre A, Lyles DS, McGettigan JP, Schnell MJ. Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses. PLoS One. 2013; 8(6):e67123. PMID: 23840600.
      View in: PubMed
    8. Lytle AG, Norton JE, Dorfmeier CL, Shen S, McGettigan JP. B cell infection and activation by rabies virus-based vaccines. J Virol. 2013 Aug; 87(16):9097-110. PMID: 23760241.
      View in: PubMed
    9. Dorfmeier CL, Shen S, Tzvetkov EP, McGettigan JP. Reinvestigating the Role of IgM in Rabies Virus Postexposure Vaccination. J Virol. 2013 Aug; 87(16):9217-22. PMID: 23760250.
      View in: PubMed
    10. Dorfmeier CL, Tzvetkov EP, Gatt A, McGettigan JP. Investigating the Role for IL-21 in Rabies Virus Vaccine-induced Immunity. PLoS Negl Trop Dis. 2013 Mar; 7(3):e2129. PMID: 23516660.
      View in: PubMed
    11. Dorfmeier CL, Lytle AG, Dunkel AL, Gatt A, McGettigan JP. Protective vaccine-induced CD4(+) T cell-independent B cell responses against rabies infection. J Virol. 2012 Nov; 86(21):11533-40. PMID: 22896601.
      View in: PubMed
    12. McGettigan JP. Experimental rabies vaccines for humans. Expert Rev Vaccines. 2010 Oct; 9(10):1177-86. PMID: 20923268.
      View in: PubMed
    13. Gomme EA, Faul EJ, Flomenberg P, McGettigan JP, Schnell MJ. Characterization of a single-cycle rabies virus-based vaccine vector. J Virol. 2010 Mar; 84(6):2820-31. PMID: 20053743.
      View in: PubMed
    14. Schnell MJ, McGettigan JP, Wirblich C, Papaneri A. The cell biology of rabies virus: using stealth to reach the brain. Nat Rev Microbiol. 2010 Jan; 8(1):51-61. PMID: 19946287.
      View in: PubMed
    15. Faul EJ, Aye PP, Papaneri AB, Pahar B, McGettigan JP, Schiro F, Chervoneva I, Montefiori DC, Lackner AA, Schnell MJ. Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. Vaccine. 2009 Dec 11; 28(2):299-308. PMID: 19879223.
      View in: PubMed
    16. Cenna J, Hunter M, Tan GS, Papaneri AB, Ribka EP, Schnell MJ, Marx PA, McGettigan JP. Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. J Infect Dis. 2009 Oct 15; 200(8):1251-60. PMID: 19764884.
      View in: PubMed
    17. Faul EJ, Wanjalla CN, McGettigan JP, Schnell MJ. Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity. Virology. 2008 Dec 20; 382(2):226-38. PMID: 18945463.
      View in: PubMed
    18. Cenna J, Tan GS, Papaneri AB, Dietzschold B, Schnell MJ, McGettigan JP. Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene. Vaccine. 2008 Nov 25; 26(50):6405-14. PMID: 18804506.
      View in: PubMed
    19. Li J, McGettigan JP, Faber M, Schnell MJ, Dietzschold B. Infection of monocytes or immature dendritic cells (DCs) with an attenuated rabies virus results in DC maturation and a strong activation of the NFkappaB signaling pathway. Vaccine. 2008 Jan 17; 26(3):419-26. PMID: 18082293.
      View in: PubMed
    20. McKenna PM, Koser ML, Carlson KR, Montefiori DC, Letvin NL, Papaneri AB, Pomerantz RJ, Dietzschold B, Silvera P, McGettigan JP, Schnell MJ. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. J Infect Dis. 2007 Apr 1; 195(7):980-8. PMID: 17330788.
      View in: PubMed
    21. Li J, Faber M, Papaneri A, Faber ML, McGettigan JP, Schnell MJ, Dietzschold B. A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice. Virology. 2006 Dec 5-20; 356(1-2):147-54. PMID: 16938327.
      View in: PubMed
    22. Smith ME, Koser M, Xiao S, Siler C, McGettigan JP, Calkins C, Pomerantz RJ, Dietzschold B, Schnell MJ. Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology. 2006 Sep 30; 353(2):344-56. PMID: 16820183.
      View in: PubMed
    23. Dave RS, McGettigan JP, Qureshi T, Schnell MJ, Nunnari G, Pomerantz RJ. siRNA targeting vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects. Virology. 2006 May 10; 348(2):489-97. PMID: 16480752.
      View in: PubMed
    24. McGettigan JP, Koser ML, McKenna PM, Smith ME, Marvin JM, Eisenlohr LC, Dietzschold B, Schnell MJ. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2. Virology. 2006 Jan 20; 344(2):363-77. PMID: 16226782.
      View in: PubMed
    25. Tan GS, McKenna PM, Koser ML, McLinden R, Kim JH, McGettigan JP, Schnell MJ. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology. 2005 Jan 5; 331(1):82-93. PMID: 15582655.
      View in: PubMed
    26. Koser ML, McGettigan JP, Tan GS, Smith ME, Koprowski H, Dietzschold B, Schnell MJ. Rabies virus nucleoprotein as a carrier for foreign antigens. Proc Natl Acad Sci U S A. 2004 Jun 22; 101(25):9405-10. PMID: 15197258.
      View in: PubMed
    27. Irie T, Licata JM, McGettigan JP, Schnell MJ, Harty RN. Budding of PPxY-containing rhabdoviruses is not dependent on host proteins TGS101 and VPS4A. J Virol. 2004 Mar; 78(6):2657-65. PMID: 14990685.
      View in: PubMed
    28. McKenna PM, Pomerantz RJ, Dietzschold B, McGettigan JP, Schnell MJ. Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes. J Virol. 2003 Dec; 77(23):12782-94. PMID: 14610200.
      View in: PubMed
    29. McGettigan JP, Naper K, Orenstein J, Koser M, McKenna PM, Schnell MJ. Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome. J Virol. 2003 Oct; 77(20):10889-99. PMID: 14512539.
      View in: PubMed
    30. McKenna PM, McGettigan JP, Pomerantz RJ, Dietzschold B, Schnell MJ. Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases. Curr HIV Res. 2003 Apr; 1(2):229-37. PMID: 15043205.
      View in: PubMed
    31. McGettigan JP, Pomerantz RJ, Siler CA, McKenna PM, Foley HD, Dietzschold B, Schnell MJ. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol. 2003 Jan; 77(1):237-44. PMID: 12477829.
      View in: PubMed
    32. McGettigan JP, McKenna PM, Schnell MJ. HIV-1 vaccines: the search continues. Clin Lab Med. 2002 Sep; 22(3):799-820, viii. PMID: 12244598.
      View in: PubMed
    33. Faber M, Pulmanausahakul R, Hodawadekar SS, Spitsin S, McGettigan JP, Schnell MJ, Dietzschold B. Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. J Virol. 2002 Apr; 76(7):3374-81. PMID: 11884563.
      View in: PubMed
    34. Siler CA, McGettigan JP, Dietzschold B, Herrine SK, Dubuisson J, Pomerantz RJ, Schnell MJ. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology. 2002 Jan 5; 292(1):24-34. PMID: 11878905.
      View in: PubMed
    McGettigan's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _